Helix Acquisition Corp. II Class A ( (HLXB) ) just unveiled an update.
On February 28, 2025, Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced a business combination agreement to form a publicly listed biotechnology company. The transaction, expected to complete in the third quarter of 2025, will provide BBOT with approximately $550 million in cash to advance its pipeline of therapies for RAS and PI3Kα malignancies. This move is anticipated to significantly impact BBOT’s operations by accelerating the development of its lead programs, potentially transforming the treatment landscape for high-prevalence cancers.
More about Helix Acquisition Corp. II Class A
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies. Initially formed as a subsidiary of BridgeBio Pharma, Inc., BBOT aims to improve outcomes for patients with cancers driven by prevalent oncogenes.
YTD Price Performance: -1.73%
Average Trading Volume: 12,454
Technical Sentiment Consensus Rating: Strong Sell
For an in-depth examination of HLXB stock, go to TipRanks’ Stock Analysis page.